Severfield PLC (SFR)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 38.10 |
|---|---|
| 52-week range | 21.30 – 41.78 |
| Return, 1 month / 3 months | +0.3% / −0.4% |
| Return, 1 year / 3 years | +36.1% / −32.8% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 46.0% |
| Worst drawdown (1 year) | -28.1% |
| Average daily value traded | 13.25M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Severfield is a structural steelwork company based in the United Kingdom. It designs, fabricates and erects steel structures for construction projects, serving clients in commercial property, infrastructure, transport and industrial markets. Its work covers building frames, bridges and other large steel frameworks, and it also provides related fabrication and construction services. The company operates from facilities in the United Kingdom and supplies contractors and developers involved in major construction schemes.
The shares are listed on the London Exchange in UK under the code SFR, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Severfield PLC (SFR) trades on the London Exchange in UK. It last closed at GBX 38.10 on 22 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 559 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 36.1% and over the last three months it fell 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.2% | ||
| From 52-week high | -3.8% | ||
| Momentum | 74 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -0.4% | ||
| 6-month return | 40.1% | ||
| 12-month return, skipping the last month | 35.7% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 46.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.1% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 13.25M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +0.3% |
| 3 months | −0.4% |
| 6 months | +40.1% |
| 1 year | +36.1% |
| 3 years | −32.8% |
| 5 years | −34.6% |
Signals
| 50-day / 200-day average | 37.98 / 31.71 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jan 2025 | GBP 0.0140 |
| 5 Sep 2024 | GBP 0.0230 |
| 4 Jan 2024 | GBP 0.0140 |
| 7 Sep 2023 | GBP 0.0210 |
| 5 Jan 2023 | GBP 0.0130 |
| 8 Sep 2022 | GBP 0.0190 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.